CN Patent

CN120173947A — 靶向凝血因子xi的核酸及其用途

Assigned to SNK Corp · Expires 2025-06-20 · 1y expired

What this patent protects

本发明涉及生物技术领域，具体地，涉及靶向凝血因子XI的核酸及其用途。本发明的核酸能够有效降低凝血因子XI水平，且能有效抑制血栓的形成，从而能够预防和/或治疗由血栓引起的多种疾病，如肺栓塞、静脉栓塞、深静脉栓塞、心肌梗塞、中风等。

USPTO Abstract

本发明涉及生物技术领域，具体地，涉及靶向凝血因子XI的核酸及其用途。本发明的核酸能够有效降低凝血因子XI水平，且能有效抑制血栓的形成，从而能够预防和/或治疗由血栓引起的多种疾病，如肺栓塞、静脉栓塞、深静脉栓塞、心肌梗塞、中风等。

Drugs covered by this patent

Patent Metadata

Patent number
CN120173947A
Jurisdiction
CN
Classification
—
Expires
2025-06-20
Drug substance claim
No
Drug product claim
No
Assignee
SNK Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.